Literature DB >> 1679886

Guillain-Barré syndrome and parenteral gangliosides.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1679886

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Bovine gangliosides and acute motor polyneuropathy.

Authors:  A Figueras; F J Morales-Olivas; D Capellà; V Palop; J R Laporte
Journal:  BMJ       Date:  1992-11-28

2.  Chronic progressive motor polyneuropathy after ganglioside treatment.

Authors:  B Schwerer; S Pichler; H Bernheimer; G Safoschnik; G Pötzl
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

Review 3.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

Review 4.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

5.  Ganglioside GM3 inhibits proliferation and invasion of glioma.

Authors:  Yasunori Fujimoto; Shuichi Izumoto; Tsuyoshi Suzuki; Manabu Kinoshita; Naoki Kagawa; Kouichi Wada; Naoya Hashimoto; Motohiko Maruno; Yuji Nakatsuji; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 6.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 7.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

8.  A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.

Authors:  N Yuki; T Taki; F Inagaki; T Kasama; M Takahashi; K Saito; S Handa; T Miyatake
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.